Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab

Mise à jour : Il y a 5 ans
Référence : NCT01730677

Femme et Homme

Extrait

The investigators address the clinical efficacy of continuing lapatinib treatment combined with vinorelbine after the progression of both trastuzumab and lapatinib treatment compared with vinorelbine alone in HER2 positive metastatic breast cancer patients.


Critère d'inclusion

  • Metastatic breast cancer

Liens